Ionis Pharmaceuticals Inc (IONS) Stock Price & Analysis

Ionis Pharmaceuticals Inc (IONS) rose 1.41% to USD 74.58 as of June 9, 2026 at 23:50 UTC, according to Nexqual real-time market data.

IONS last closed at USD 73.54; the session ranged USD 73.53–75.79 on volume of 1,546,288 shares. Market capitalization is $12.33B, with a 52-week range of USD 34.78–86.74 (NMS). Source: Nexqual, June 9, 2026 at 23:50 UTC.

Key Statistics (as of June 9, 2026 at 23:50 UTC)

Technical Analysis (IONS)

Nexqual's technical model rates IONS "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:50 UTC.

Analyst Ratings (IONS)

Wall Street analysts rate IONS "Buy" based on 25 analysts, with a mean price target of USD 100.92 (range USD 47–130), per Nexqual as of June 9, 2026 at 23:50 UTC.

Earnings (IONS)

Recent Earnings History

Source: Nexqual, June 9, 2026 at 23:50 UTC.

Financials & Fundamentals (IONS)

Source: Nexqual, June 9, 2026 at 23:50 UTC.

Financial Health Score (IONS)

Nexqual rates Ionis Pharmaceuticals Inc's overall financial health "Weak" across five dimensions, as of June 9, 2026 at 23:50 UTC.

Ownership (IONS)

Source: Nexqual, June 9, 2026 at 23:50 UTC.

Leadership (IONS)

Ionis Pharmaceuticals Inc is led by Brett P. Monia (age 64), Founder, CEO & Director, per Nexqual as of June 9, 2026 at 23:50 UTC.

Major Backers & Investors (IONS)

Notable institutional backers of Ionis Pharmaceuticals Inc include FMR, LLC, Capital Group, Fidelity, according to Nexqual as of June 9, 2026 at 23:50 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 9, 2026 at 23:50 UTC.

From Ionis Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• The FDA also granted Fast Track designation to ulefnersen.   11   Our Innovative Mid-Stage Pipeline of Investigational Medicines   We also have a rich mid-stage pipeline with numerous potentially transformational investigational medicines, including both Ionis-owned and partnered therapies.
• From inception through December 31, 2025, we recognized more than $2.5 billion in total revenue under this collaboration, including more than $2.0 billion in revenue from SPINRAZA royalties and more than $425 million in R&D revenue.   We have exclusively in-licensed patents related to SPINRAZA from Cold Spring Harbor Laboratory and the University of Massachusetts.
• Our technology enables us to change the function or expression of a gene in a highly specific and directed manner, which, in turn, can help address the root cause of a disease.   For example, a gene called TTR contains instructions to make TTR protein, which can accumulate in tissues and cause disease.
• Our technology can also increase or change the expression of a gene.

Partnerships

• PTC is commercializing WAYLIVRA in Brazil and is pursuing access in additional Latin American countries through its exclusive license agreement with us.   WAYLIVRA's conditional marketing authorization in the EU for FCS and approval in Brazil for FCS we re based on efficacy and safety data from the Phase 3 APPROACH study and supported by results from the Phase 3 COMPASS study.
• From inception through December 31, 2025, we have generated more than $420 million in payments under this collaboration.   Biogen   Marketed Medicines   SPINRAZA   In 2012, we entered into a collaboration agreement with Biogen to develop and commercialize SPINRAZA.   We are receiving tiered royalties ranging from 11 percent to 15 percent on sales of SPINRAZA.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:50 UTC. This page is informational and not investment advice.